Success Stories: EB-1A Approved for CEO in Massachusetts in the Field of Medical Biology

 

Client’s Testimonial:

 

This is incredible. Many many thanks for your professionalism and diligence in putting things together.

 


On April 28th, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a CEO in the Field of Medical Biology (Approval Notice)


General Field: Medical Biology

Position at the Time of Case Filing: CEO

Country of Origin: India

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: April 28th, 2015

Processing Time: 25 days (11 days after premium processing was requested)

 

 


Case Summary:

In this case, the client that we had the opportunity to work with was a CEO from India in the field of Medical Biology.  He had conducted his research in the highly specialized topic of the influence of polymorphisms on drug behavior in cancer patients. His work had resulted in 14 peer-reviewed scientific articles and numerous presentations at national and international conferences; at the time that his case was filed, his publications had been cited at least 354 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work.  He had also reviewed 6 manuscripts for distinctive, internationally-circulated journals.  His superior level of expertise was confirmed in the following quote from an independent recommender, “Advanced research like [Client]’s is helping researchers and health professionals alike determine the root causes of heart disease and giving them greater insight on how non-modifiable risk factors (age, gender, heredity) affect an individual’s chances of getting diagnosed with coronary artery disease.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Medical Biology, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 25 days.